ArticleOncotarget2016
Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Silvia Darb-Esfahani et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
48 papers cite it
this papertrialcites it